Skip to main content
SpringerLink
Log in

Chemotherapieinduzierte Nausea und Emesis

Aktuelle Empfehlungen zur Prophylaxe

Chemotherapy-induced nausea and vomiting

Current recommendations for prophylaxis

  • Leitthema
  • Published:
Der Urologe Aims and scope Submit manuscript

Zusammenfassung

Die chemotherapieinduzierte Nausea und Emesis (CINE) gehören zu den häufigsten Nebenwirkungen der Zytostatikatherapie und stellen bei der Behandlung onkologischer Patienten eine große Herausforderung dar. Eine korrekte, leitliniengerechte antiemetische Prophylaxe ist daher unerlässlich und trägt wesentlich zum Behandlungserfolg bei. Diese Übersichtsarbeit fasst die aktuellen Empfehlungen der „Multinational Association of Supportive Care in Cancer“ (MASCC) und „European Society of Medical Oncology“ (ESMO), der „American Society for Clinical Oncology“ (ASCO), des „National Comprehensive Cancer Network“ (NCCN) sowie der S3-Leitlinie „Supportive Therapie“ vom „Leitlinienprogramm Onkologie“ zur Prophylaxe der CINE verständlich zusammen und soll deren Anwendung in der täglichen Routine erleichtern.

Abstract

The chemotherapy-induced nausea and vomiting (CINV) is one of the most frequent side effects in cytostatic therapy and a profound challenge during the therapy of cancer patients. Therefore, standardized guideline-orientated prophylaxis is essential and a fundamental contribution for the success of treatment. This review summarizes the current recommendations for CINV of the Multinational Association of Supportive Care in Cancer (MASCC) and European Society of Medical Oncology (ESMO), the American Society for Clinical Oncology (ASCO), the National Comprehensive Cancer Network (NCCN) and the S3-guideline Supportive Therapie of the Leitlinienprogramm Onkologie and shall facilitate its use in the daily routine.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Abb. 1
Abb. 2
Abb. 3
Abb. 4

Abbreviations

5-HT:

5-Hydroxytryptamin (Serotonin)

5-HT3-Rezeptoren:

5‑Hydroxytryptamin-3-Rezeptoren

ANS:

Antineoplastische Substanz

ASCO:

American Society for Clinical Oncology

AUC:

„Area under the curve“

AUO:

Arbeitsgemeinschaft Urologische Onkologie

BfArM:

Bundesinstitut für Arzneimittel und Medizinprodukte

BID:

bis in die (lat.: zweimal täglich)

CINE:

Chemotherapiebedingte Nausea und Emesis

CYP:

Cytochrom P

ESMO:

European Society of Medical Oncology

i. v.:

intravenös

INR:

International Normalized Ratio

MASCC:

Multinational Association of Supportive Care in Cancer

MCP:

Metoclopramid

NCCN:

National Comprehensive Cancer Network

NK1-Rezeptor:

Neurokinin-Rezeptor 1

ZNS:

Zentrales Nervensystem

Literatur

  1. AOP (2016) Fachinformation zu CANEMES 1 mg Kaps. http://sr001017043/detailinfo.php?ID=3348522200. Zugegriffen: 02.01.18

  2. Deutsche Krebsgesellschaft, Deutsche Krebshilfe, AWMF (2017) Leitlinienprogramm Onkologie: S3-Leitlinie Supportive Therapie bei onkologischen PateintInnen, Langversion 1.1, April 2017, AWMF Registrierungsnummer 032/054OL. http://leitlinienprogramm-onkologie.de/. Zugegriffen: 9. Dez. 2017

    Google Scholar 

  3. Aapro M, Rugo H, Rossi G et al (2014) A randomized phase III study evaluating the efficacy and safety of NEPA, a fixed-dose combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy. Ann Oncol 25:1328–1333

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Aapro MS, Molassiotis A, Olver I (2005) Anticipatory nausea and vomiting. Support Care Cancer 13:117–121

    Article  PubMed  Google Scholar 

  5. Bymaster FP, Calligaro DO, Falcone JF et al (1996) Radioreceptor binding profile of the atypical antipsychotic olanzapine. Neuropsychopharmacology 14:87–96

    Article  CAS  PubMed  Google Scholar 

  6. Coates A, Abraham S, Kaye SB et al (1983) On the receiving end—patient perception of the side-effects of cancer chemotherapy. Eur J Cancer Clin Oncol 19:203–208

    Article  CAS  PubMed  Google Scholar 

  7. Cohen L, de Moor CA, Eisenberg P et al (2007) Chemotherapy-induced nausea and vomiting: incidence and impact on patient quality of life at community oncology settings. Support Care Cancer 15:497–503

    Article  PubMed  Google Scholar 

  8. Dando TM, Perry CM (2004) Aprepitant: a review of its use in the prevention of chemotherapy-induced nausea and vomiting. Drugs 64:777–794

    Article  CAS  PubMed  Google Scholar 

  9. Ettinger DS, Berger MJ, Aston J et al (2017) NCCN guidelines; Antiemesis, version 2.2017. http://nccn.org. Zugegriffen: 9. Dez. 2017

    Google Scholar 

  10. Geling O, Eichler HG (2005) Should 5‑hydroxytryptamine-3 receptor antagonists be administered beyond 24 hours after chemotherapy to prevent delayed emesis? Systematic re-evaluation of clinical evidence and drug cost implications. J Clin Oncol 23:1289–1294

    Article  CAS  PubMed  Google Scholar 

  11. Gralla RJ, Bosnjak SM, Hontsa A et al (2014) A phase III study evaluating the safety and efficacy of NEPA, a fixed-dose combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting over repeated cycles of chemotherapy. Ann Oncol 25:1333–1339

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Gralla RJ, Itri LM, Pisko SE et al (1981) Antiemetic efficacy of high-dose metoclopramide: randomized trials with placebo and prochlorperazine in patients with chemotherapy-induced nausea and vomiting. N Engl J Med 305:905–909

    Article  CAS  PubMed  Google Scholar 

  13. Gralla RJ, Osoba D, Kris MG et al (1999) Recommendations for the use of antiemetics: evidence-based, clinical practice guidelines. American Society of Clinical Oncology. J Clin Oncol 17:2971–2994

    Article  CAS  PubMed  Google Scholar 

  14. Grunberg S, Chua D, Maru A et al (2011) Single-dose fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with cisplatin therapy: randomized, double-blind study protocol–EASE. J Clin Oncol 29:1495–1501

    Article  CAS  PubMed  Google Scholar 

  15. Grunberg SM (2004) Chemotherapy-induced nausea and vomiting: prevention, detection, and treatment—how are we doing? J Support Oncol 2:1–12

    PubMed  Google Scholar 

  16. Grunberg SM, Deuson RR, Mavros P et al (2004) Incidence of chemotherapy-induced nausea and emesis after modern antiemetics. Cancer 100:2261–2268

    Article  PubMed  Google Scholar 

  17. Grunberg SM, Osoba D, Hesketh PJ et al (2005) Evaluation of new antiemetic agents and definition of antineoplastic agent emetogenicity—an update. Support Care Cancer 13:80–84

    Article  PubMed  Google Scholar 

  18. Hesketh PJ, Aapro M, Street JC et al (2010) Evaluation of risk factors predictive of nausea and vomiting with current standard-of-care antiemetic treatment: analysis of two phase III trials of aprepitant in patients receiving cisplatin-based chemotherapy. Support Care Cancer 18:1171–1177

    Article  PubMed  Google Scholar 

  19. Hesketh PJ, Grunberg SM, Gralla RJ et al (2003) The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin–the Aprepitant Protocol 052 Study Group. J Clin Oncol 21:4112–4119

    Article  CAS  PubMed  Google Scholar 

  20. Hesketh PJ, Kris MG, Basch E et al (2017) Antiemetics: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol 35:3240–3261

    Article  PubMed  Google Scholar 

  21. Hesketh PJ, Kris MG, Grunberg SM et al (1997) Proposal for classifying the acute emetogenicity of cancer chemotherapy. J Clin Oncol 15:103–109

    Article  CAS  PubMed  Google Scholar 

  22. Jordan K, Gralla R, Jahn F et al (2014) International antiemetic guidelines on chemotherapy induced nausea and vomiting (CINV): content and implementation in daily routine practice. Eur J Pharmacol 722:197–202

    Article  CAS  PubMed  Google Scholar 

  23. Kamen C, Tejani MA, Chandwani K et al (2014) Anticipatory nausea and vomiting due to chemotherapy. Eur J Pharmacol 722:172–179

    Article  CAS  PubMed  Google Scholar 

  24. Licup N (2010) Olanzapine for nausea and vomiting. Am J Hosp Palliat Care 27:432–434

    Article  PubMed  Google Scholar 

  25. Navari RM (2014) Olanzapine for the prevention and treatment of chronic nausea and chemotherapy-induced nausea and vomiting. Eur J Pharmacol 722:180–186

    Article  CAS  PubMed  Google Scholar 

  26. Navari RM (2015) Profile of netupitant/palonosetron (NEPA) fixed dose combination and its potential in the treatment of chemotherapy-induced nausea and vomiting (CINV). Drug Des Devel Ther 9:155–161

    CAS  PubMed  Google Scholar 

  27. Navari RM, Einhorn LH, Passik SD et al (2005) A phase II trial of olanzapine for the prevention of chemotherapy-induced nausea and vomiting: a Hoosier Oncology Group study. Support Care Cancer 13:529–534

    Article  PubMed  Google Scholar 

  28. Navari RM, Gray SE, Kerr AC (2011) Olanzapine versus aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a randomized phase III trial. J Support Oncol 9:188–195

    Article  CAS  PubMed  Google Scholar 

  29. Navari RM, Nagy CK, Gray SE (2013) The use of olanzapine versus metoclopramide for the treatment of breakthrough chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy. Support Care Cancer 21:1655–1663

    Article  PubMed  Google Scholar 

  30. Perwitasari DA, Gelderblom H, Atthobari J et al (2011) Anti-emetic drugs in oncology: pharmacology and individualization by pharmacogenetics. Int J Clin Pharm 33:33–43

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  31. Poli-Bigelli S, Rodrigues-Pereira J, Carides AD et al (2003) Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy-induced nausea and vomiting. Results from a randomized, double-blind, placebo-controlled trial in Latin America. Cancer 97:3090–3098

    Article  CAS  PubMed  Google Scholar 

  32. Raftopoulos H, Cooper W, O’Boyle E et al (2015) Comparison of an extended-release formulation of granisetron (APF530) versus palonosetron for the prevention of chemotherapy-induced nausea and vomiting associated with moderately or highly emetogenic chemotherapy: results of a prospective, randomized, double-blind, noninferiority phase 3 trial. Support Care Cancer 23:723–732

    Article  PubMed  Google Scholar 

  33. Rapoport B, Chua D, Poma A et al (2015) Study of rolapitant, a novel, long-acting, NK-1 receptor antagonist, for the prevention of chemotherapy-induced nausea and vomiting (CINV) due to highly emetogenic chemotherapy (HEC). Support Care Cancer 23:3281–3288

    Article  PubMed  Google Scholar 

  34. Rapoport BL, Chasen MR, Gridelli C et al (2015) Safety and efficacy of rolapitant for prevention of chemotherapy-induced nausea and vomiting after administration of cisplatin-based highly emetogenic chemotherapy in patients with cancer: two randomised, active-controlled, double-blind, phase 3 trials. Lancet Oncol 16:1079–1089

    Article  CAS  PubMed  Google Scholar 

  35. Rapoport BL, Jordan K, Boice JA et al (2010) Aprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with a broad range of moderately emetogenic chemotherapies and tumor types: a randomized, double-blind study. Support Care Cancer 18:423–431

    Article  PubMed  Google Scholar 

  36. Roila F, Molassiotis A, Herrstedt J et al (2016) 2016 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting and of nausea and vomiting in advanced cancer patients. Ann Oncol 27(v119):v133

    Google Scholar 

  37. Schwartzberg L, Barbour SY, Morrow GR et al (2014) Pooled analysis of phase III clinical studies of palonosetron versus ondansetron, dolasetron, and granisetron in the prevention of chemotherapy-induced nausea and vomiting (CINV). Support Care Cancer 22:469–477

    Article  PubMed  Google Scholar 

  38. Shadle CR, Lee Y, Majumdar AK et al (2004) Evaluation of potential inductive effects of aprepitant on cytochrome P450 3A4 and 2C9 activity. J Clin Pharmacol 44:215–223

    Article  CAS  PubMed  Google Scholar 

  39. Spartinou A, Nyktari V, Papaioannou A (2017) Granisetron: a review of pharmacokinetics and clinical experience in chemotherapy induced—nausea and vomiting. Expert Opin Drug Metab Toxicol 13:1289–1297

    Article  CAS  PubMed  Google Scholar 

  40. Tafelski S, Hauser W, Schafer M (2016) Efficacy, tolerability, and safety of cannabinoids for chemotherapy-induced nausea and vomiting—a systematic review of systematic reviews. Schmerz 30:14–24

    Article  CAS  PubMed  Google Scholar 

  41. Tageja N, Groninger H (2016) Chemotherapy-induced nausea and vomiting: an overview and comparison of three consensus guidelines. Postgrad Med J 92:34–40

    Article  CAS  PubMed  Google Scholar 

  42. Warr D (2014) Prognostic factors for chemotherapy induced nausea and vomiting. Eur J Pharmacol 722:192–196

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Urologische Klinik und Poliklinik, Klinikum rechts der Isar, Technische Universität München, Ismaninger Str. 22, 81675, München, Deutschland

    E. Storz, J. E. Gschwend & M. Retz

Authors
  1. E. Storz
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. J. E. Gschwend
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. M. Retz
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to E. Storz.

Ethics declarations

Interessenkonflikt

E. Storz, J. E. Gschwend und M. Retz geben an, dass kein Interessenkonflikt besteht.

Dieser Beitrag beinhaltet keine von den Autoren durchgeführten Studien an Menschen oder Tieren.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Storz, E., Gschwend, J.E. & Retz, M. Chemotherapieinduzierte Nausea und Emesis. Urologe 57, 532–542 (2018). https://doi.org/10.1007/s00120-018-0606-6

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00120-018-0606-6

Schlüsselwörter

Keywords

Search

Navigation